Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

LEIDEN, The Netherlands, December 17 /PRNewswire/ --

- Researchers Expect Groundbreaking Results

Today Top Institute Pharma presents a new and highly promising research project. The TI Pharma project is a large-scale study into the brain material of Alzheimer's and Parkinson's patients, who gave permission to the Netherlands Brain Bank for their tissue to be used for scientific research. The analysis is a continuation of highly-promising results from previous studies and focuses on the genes that could be involved in the development of Alzheimer's disease and Parkinson's disease. The study - that must form the basis for potential drugs - is one of the largest to be carried out on an international level.

LONDON, December 14 /PRNewswire/ --

- The Benefits of Anastrozole (Arimidex(R)) Over Tamoxifen at Preventing Breast Cancer Recurrence Improve Over Time - Up to Four Years After Treatment Ends

New data from ATAC(x), one of the world's largest and longest-running studies in postmenopausal women with hormone receptor positive (HR+), early breast cancer, reinforce that anastrozole can help many more women live cancer-free, for longer. The new data show that post-menopausal HR+ women continue to benefit from anastrozole, even up to four years after treatment ends.(1), (2) If breast cancer returns, women are much more likely to die - therefore, preventing breast cancer recurrence is fundamental to saving lives.

SLOUGH, England, December 14 /PRNewswire/ -- Reckitt Benckiser, the manufacturer of Nurofen Plus, has been made aware of the death of a woman earlier this year from acute renal failure who, prior to her death, was taking large quantities of Nurofen Plus (in excess of 48 tablets) daily. This far exceeds the recommended and approved doses (a maximum of six tablets daily).

A Reckitt Benckiser spokesperson comments, "We offer our sincere sympathy to the Docherty family for their tragic loss. However, Reckitt Benckiser would like to reassure consumers that Nurofen Plus, and all other products in the Nurofen range, are safe and effective when taken in accordance with the pack instructions, and used to effectively relieve pain by millions of people every day."

KYIV, Ukraine, December 14 /PRNewswire/ --

Bloc of Yulia Tymoshenko (BYuT) Deputies Viktor Pynzennyk, Yuriy Prodan, and Hryhoriy Nemyria met today in Kyiv with four of the largest foreign creditors of Naftohaz Ukraine, Ukraine's state-owned oil and gas company. Investment bankers requested the meeting with BYuT to address Naftohaz Ukraine's precarious financial situation.

LONDON, December 14 /PRNewswire/ -- In response to comments made by Coroner Simon Nelson at the inquest of Linda Docherty of Bury, Greater Manchester, David Pruce, Head of Practice and Quality Improvement said:

"The Royal Pharmaceutical Society of Great Britain would like to express its concern at hearing of Mrs Docherty's death, following her addiction to Nurofen Plus."

"Pharmacists are highly skilled professionals and the public benefit from access to a wide range of medicines of this type over the counter. Medicines available over the counter can only be purchased in limited quantities."

WASHINGTON, December 14 /PRNewswire/ --

- New education index sheds light on opportunities for investment in Africa

This month School Ventures launched the African Private Schools Investment Index ("APSI"), developed in cooperation with the Economist Intelligence Unit. The APSI is an analytical tool for investors, policy makers, philanthropists, educationalists, and the general public. It compares the attractiveness of African education markets as destinations for private investment.